5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮结构式
|
常用名 | 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮 | 英文名 | C-1311 |
|---|---|---|---|---|
| CAS号 | 138154-39-9 | 分子量 | 350.41400 | |
| 密度 | 1.32g/cm3 | 沸点 | 605.8ºC at 760mmHg | |
| 分子式 | C20H22N4O2 | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | 320.2ºC | |
| 符号 |
GHS07 |
信号词 | Warning |
用途Symadex, also known as imidazoacridone; XLS-002 and C-1311, is a member of the novel imidazoacridinone family of anticancer agents. Imidazoacridone has shown activity in experimental tumour models both in vitro and in nude mice. C-1311 at the EC(99) dose delayed progression of cells through the S phase which was followed by G2 arrest. C-1311 does not induce rapid apoptosis in HT-29 cells, instead drug exposure leads to prolonged G2 arrest followed by G2 to M transit and cell death during mitosis in the process of mitotic catastrophe. |
摘要:5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮,又称Symadex或C-1311,其CAS号为138154-39-9,分子式为C20H22N4O2,分子量为350.41400。该化合物是一种新型咪唑并吖啶抗癌剂,具有体内外抗肿瘤活性。C-1311通过延长G2期阻滞并最终导致有丝分裂灾难而诱导细胞死亡。仅供科研实验参考,不作为医疗或临床使用依据。
本表展示该化学物质的中文名称、英文系统名、各类中文与英文别名信息。
| 中文名 | 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮 |
|---|---|
| 英文名 | 5-((2-(diethylamino)ethyl)amino)-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one |
| 英文别名 | 更多 |
本表包含该物质理化参数,如熔点、沸点、密度、溶解度、旋光性等理化指标,无数据项标记为N/A。
| 密度 | 1.32g/cm3 |
|---|---|
| 沸点 | 605.8ºC at 760mmHg |
| 分子式 | C20H22N4O2 |
| 分子量 | 350.41400 |
| 闪点 | 320.2ºC |
| 精确质量 | 350.17400 |
| PSA | 69.87000 |
| LogP | 2.97100 |
| InChIKey | CUNDRHORZHFPLY-UHFFFAOYSA-N |
| SMILES | CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23 |
| 蒸汽压 | 2.86E-15mmHg at 25°C |
| 折射率 | 1.68 |
本表提供该化合物公开报道的合成路线、反应条件、反应物与产物参考信息。
|
~%
5-((2-(二乙基氨基)乙基... 138154-39-9 |
| 文献:Journal of Medicinal Chemistry, , vol. 54, # 19 p. 6597 - 6611 |
|
~%
5-((2-(二乙基氨基)乙基... 138154-39-9 |
| 文献:Journal of Medicinal Chemistry, , vol. 54, # 19 p. 6597 - 6611 |
|
~%
5-((2-(二乙基氨基)乙基... 138154-39-9 |
| 文献:Journal of Medicinal Chemistry, , vol. 54, # 19 p. 6597 - 6611 |
|
~%
5-((2-(二乙基氨基)乙基... 138154-39-9 |
| 文献:Journal of Medicinal Chemistry, , vol. 54, # 19 p. 6597 - 6611 |
|
~%
5-((2-(二乙基氨基)乙基... 138154-39-9 |
| 文献:Journal of Medicinal Chemistry, , vol. 54, # 19 p. 6597 - 6611 |
本表列出该化学品对应的上游起始原料以及下游衍生产物清单。
| 上游产品 3 | |
|---|---|
| 下游产品 0 | |
本表为该化合物相关公开文献,包含文献标题、期刊、发表信息等参考资料。
|
DNA-damaging imidazoacridinone C-1311 induces autophagy followed by irreversible growth arrest and senescence in human lung cancer cells.
J. Pharmacol. Exp. Ther. 346(3) , 393-405, (2013) Imidazoacridinone 5-diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311) is an antitumor inhibitor of topoisomerase II and FMS-like tyrosine kinase 3 receptor. In this study, we describe the uni... |
|
|
Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.
Drug Metab. Dispos. 41(2) , 414-21, (2013) The acridinone derivates 5-dimethylaminopropylamino-8-hydroxytriazoloacridinone (C-1305) and 5-diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311) are promising antitumor agents with high activ... |
|
|
Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.
J. Pharm. Biomed. Anal. 39(1-2) , 46-53, (2005) C1311 (5-[[2-(diethylamino)ethyl]amino]-8-hydroxyimidazo [4,5,1-de]-acridin-6-one-dihydrochloride trihydrate) is the lead compound from the group of imidazoacridinones, a novel group of rationally des... |
本表记录该化合物靶点、体外体内实验、生物测定实验相关实验数据。
本表罗列该化合物全部英文别名、系统命名、CAS别名等英文名称集合。
| 5-[[(diethylamino)ethyl]amino]-8-hydroxyimidazo[4,5,1-de]-acridine-6-one |
| C 1311 |
| XLS-002 |
| 6H-Imidazo(4,5,1-de)acridin-6-one,5-((2-(diethylamino)ethyl)amino)-8-hydroxy |
| 5-((2-(Diethylamino)ethyl)amino)-8-hydroxy-6H-imidazo(4,5,1-de)acridin-6-one |
本部分为该化合物相关常见问答,包含基础参数、性状、储存条件等高频咨询问题与对应答案。
| Q: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮的极性表面积PSA是多少? |
| A: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮极性表面积PSA为69.87000。 |
| Q: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮的SMILES表达式是什么? |
| A: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮SMILES表达式为CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23。 |
| Q: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮的InChIKey是什么? |
| A: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮InChIKey为CUNDRHORZHFPLY-UHFFFAOYSA-N。 |
| Q: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮有哪些英文别名? |
| A: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮英文别名有:5-[[(diethylamino)ethyl]amino]-8-hydroxyimidazo[4,5,1-de]-acridine-6-one、 C 1311、 XLS-002、 6H-Imidazo(4,5,1-de)acridin-6-one,5-((2-(diethylamino)ethyl)amino)-8-hydroxy、 5-((2-(Diethylamino)ethyl)amino)-8-hydroxy-6H-imidazo(4,5,1-de)acridin-6-one。 |
| Q: 138154-39-9的中文名称是什么? |
| A: 138154-39-9的中文名称为5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮。 |
| Q: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮的LogP(油水分配系数)是多少? |
| A: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮LogP(油水分配系数)为2.97100。 |
| Q: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮的分子式是什么? |
| A: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮分子式为C20H22N4O2。 |
| Q: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮的分子量是多少? |
| A: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮分子量为350.41400。 |
| Q: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮的英文名称是什么? |
| A: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮英文名称为5-((2-(diethylamino)ethyl)amino)-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one。 |
| Q: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮的CAS号是多少? |
| A: 5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮CAS号为138154-39-9。 |